Asia Pacific Leukemia Therapeutics Market is Segmented By Cancer Type (Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Others), By Therapy (Targeted Therapy, Chemotherapy, Immunotherapy, Others), By End-User (Hospitals, Specialty Clinics, Homecare, Others), and By Country (India, China, Japan) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Asia Pacific leukemia therapeutics market reached US$ 340 million in 2023 and is expected to reach US$ 567.18 million by 2031, growing at a CAGR of 6.7% during the forecast period 2024-2031.
Leukemia is a blood cancer that occurs when the bone marrow produces abnormal white blood cells, also called blasts or leukemia cells. These abnormal cells can't fight infections and prevent the bone marrow from producing healthy red blood cells and platelets. Leukemia can spread to the lymph nodes, bloodstream, brain, spinal cord, and other parts of the body. If it spreads to the brain, symptoms may include headaches, seizures, balance problems, or vision problems.
If it spreads to the lymph nodes in the chest, symptoms may include breathing problems and chest pain. For the treatment of lymphoma various therapies such as targeted therapy, chemotherapy, immunotherapy, CAR T cell therapy, stem cell transplantation, and radiation therapy are used depending upon the type of leukemia and condition of the leukemia.
Market Scope
| Metrics | Details |
| CAGR | 6.7% |
| Market Size | 2022-2031 |
| Market Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Cancer Type, Therapy, and End-User |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Increasing prevalence of leukemia
The demand for the leukemia therapeutics market is driven by multiple factors. For instance, according to the International Agency for Research on Cancer, in 2022 more than 70,000 people lost their lives due to blood cancer in India the report also states that the country is currently seeing a surge in the number of blood cancer cases getting diagnosed which tolls at a whopping 1,20,000 in contrast to the previous report which showed an incidence rate of 1,00,000 where out of the total cases 30,000 are those seen in children.
Over 70% of the patients diagnosed with blood cancer or blood disorder in India are unable to find a match within their families and urgently need a matching unrelated donor. Moreover, according to the Leukaemia Foundation, blood cancer is one of the highest causes of cancer death in Australia, it is expected that 19,403 Australians will be newly diagnosed with blood cancers such as leukemia, lymphoma, and myeloma. This is equivalent to 53 people per day or one person every 27 minutes. The incidence of blood cancer continues to grow. The incidence of blood cancer has increased by 47% in the past 10 years. Around 135,000 people are living with a blood cancer or blood disorder in Australia. By 2035, more than 275,000 Australians are expected to be living with a blood cancer or blood disorder.
Restraints
Factors such as high costs associated with the treatment and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. For instance, according to the National Institute of Health, the cumulative drug cost for 1 year of alemtuzumab which is used in the treatment of chronic leukemia, is US$ 70,000. Higher costs of drugs which affect the drug affordability of many people are one of the aspects that acts as a restraint to the Asia Pacific leukemia therapeutics market.
Market Segment Analysis
The Asia Pacific leukemia therapeutics market is segmented based on cancer type, therapy, end-user, and region.
The targeted therapy accounted for approximately 56.5% of the Asia Pacific leukemia therapeutics market share.
The targeted therapy segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for clinical trials would drive this market.
Targeted therapy drugs are the first line of treatment for certain types of leukemia. These medicines find and target specific proteins or changes in cells that cause leukemia. Unlike chemotherapy (which affects healthy and diseased cells), targeted therapy focuses only on the cell changes that cause the cancer. The drugs cause minimal, if any, damage to healthy cells. There are different types of targeted therapy drugs for leukemia. The lab-made drugs can find specific substances in leukemia cells, such as proteins or genetic (DNA) changes. The drugs then damage or destroy the diseased cells.
For instance, in October 2023, India’s counterpart to the US Food and Drug Administration, the Central Drugs Standard Control Organization, made NexCAR19 India’s first approved CAR-T cell therapy. ImmunoACT, a spin-off company of IIT Bombay, funded the trial and will be manufacturing actalycabtagene autoleucel and bringing it to market.
Market Segmentation
By Cancer Type
- Chronic Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Others
By Therapy
- Targeted Therapy
- Bosutinib
- Venetoclax
- Chemotherapy
- Rituximab
- Dasatinib
- Immunotherapy
- Ofatumumab
- Brexucabtagene autoleucel
- Others
By End-User
- Hospitals and Clinics
- Cancer Centers
- Ambulatory Surgical Centers
- Others
Competitive Landscape
The major players in the Asia Pacific leukemia therapeutics market include Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis AG, Bristol-Myers Squibb, Sun Pharmaceutical Industries Ltd., Dr.Reddy’s Laboratories Ltd., Aurobindo Pharma, Lupin, Clavis Pharma, and Pfizer Inc. among others.
Key Developments
- In July 2024, Alembic Pharmaceuticals Limited announced that it had received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bosutinib Tablets, 100 mg and 500 mg. Bosutinib tablets are indicated for the treatment of a certain type of leukemia called Philadelphia chromosome-positive chronic myelogenous leukemia.
- In February 2024, the U.S. Food and Drug Administration approved a bi-weekly dose of Johnson & Johnson's blood cancer therapy Tecvayli. The approval allows the therapy to be used in a reduced dosing of 1.5 milligrams per kilogram every two weeks, in patients who have achieved and maintained a complete response or better for a minimum of six months.
Why Purchase the Report?
- To visualize the Asia Pacific leukemia therapeutics market segmentation based on cancer type, therapy, and end-user, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of Asia Pacific leukemia therapeutics market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in Excel consisting of key products of all the major players.
The Asia Pacific leukemia therapeutics market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
